1 Nafamostat-interferon-alpha combination suppresses 2 SARS-CoV-2 infection by targeting cooperatively host 3 TMPRSS2 in vitro and in vivo

4 Aleksandr Ianevski ^{1*}, Rouan Yao ¹, Hilde Lysvand ¹, Gunnveig Grødeland ^{2,3,4}, Nicolas Legrand ⁵, Valentin
5 Oksenyich ¹, Eva Zusinaite ⁶, Tanel Tenson ⁶, Magnar Bjørås ¹, Denis E. Kainov ^{1,6,7 *}

6 ¹ Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology,
7 7028, Trondheim, Norway

8 ² Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372, Oslo, Norway

9 ³ Institute of Clinical Medicine (KlinMed), University of Oslo, 0318, Oslo, Norway

10 ⁴ Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, 0372, Oslo,
11 Norway

12 ⁵ Oncodesign, 25 Avenue du Québec, 91140 Villebon Sur Yvette, France

13 ⁶ Institute of Technology, University of Tartu, 50411 Tartu, Estonia

14 ⁷ Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014, Helsinki, Finland

15 * Corresponding author

16

17 SARS-CoV-2 and its vaccine/immune-escaping variants continue to pose a serious threat to public health
18 due to a paucity of effective, rapidly deployable, and widely available treatments. Here, we address these
19 challenges by combining Pegasys (IFNa) and nafamostat to effectively suppress SARS-CoV-2 infection in cell
20 culture and hamsters. Our results indicate that Serpin E1 is an important mediator of the antiviral activity of
21 IFNa and that both Serpin E1 and camostat can target the same cellular factor TMPRSS2, which plays a critical
22 role in viral replication. The low doses of the drugs in combination may have several clinical advantages,
23 including fewer adverse events and improved patient outcome. Thus, our study may provide a proactive
24 solution for the ongoing pandemic and potential future coronavirus outbreaks, which is still urgently required in
25 many parts of the world.

26 **Introduction**

27 Over the past 10 years, there have been four major viral epidemics/pandemics for which the world was
28 unprepared. The current pandemic concerns the SARS-CoV-2 virus, which has infected over 281 million people
29 globally, killed over 3.9 million, devastated economies, and caused other unfathomable hardships. The challenge
30 addressed in this study is a tragic lack of effective antiviral drugs that can be deployed to treat SARS-CoV-2
31 infection.

32 So far, many monotherapies have been tested, but all have been shown to be ineffective or had limited
33 efficacy against COVID-19 [1]. By contrast, combinational therapies are emerging as a useful tool to treat SARS-
34 CoV-2 infection [2]. Synergistic combinational therapies can achieve better efficacy while requiring lower dosage
35 compared to monotherapies, therefore, inducing fewer and milder adverse effects. Additionally, antiviral
36 combinations could target emerging SARS-CoV-2 variants and prevent the development of strains resistant to
37 monotherapies.

38 Our recent studies have highlighted the synergism of several compounds against SARS-CoV-2 in human
39 lung epithelial Calu-3 cells, with IFNa-remdesivir and camostat-remdesivir combinations having the highest
40 synergy scores [2-4]. In these studies, we were also able to show that camostat-remdesivir was effective against
41 SARS-CoV-2 infection in human lung organoids, as well as that IFNa-remdesivir was effective in both human
42 lung organoids and Syrian hamsters [3, 4]. Furthermore, other studies have shown that combinations of IFNa
43 with lopinavir-ritonavir-ribavirin as well as nafamostat with favipiravir are effective for treatment of patients
44 infected with SARS-CoV-2 [5, 6].

45 Nafamostat, a structural analogue of camostat, is a repurposed drug which was originally approved as a
46 short-acting anticoagulant and is also used for the treatment of pancreatitis [7]. It is currently in clinical trials for
47 treatment of COVID-19 (NCT04623021, NCT04473053, NCT04390594, NCT04483960). IFNas and its pegylated
48 forms are also repurposed drugs which have been shown to be effective for COVID-19 patients [8, 9]. Because
49 previous studies have demonstrated the high therapeutic potential of both nafamostat and IFNa as separate
50 antiviral treatments, we hypothesized that IFNa-nafamostat combinational therapy may represent an even more
51 practical therapeutic option against SARS-CoV-2 infection.

52 **Results and discussion**

53 To test our hypothesis, we first analyzed toxicity and efficacy of Pegasys (pegylated IFNa) and nafamostat,
54 against mCherry-expressing SARS-CoV-2 [10] in human lung epithelial Calu-3 cells using fluorescence and cell

viability assay as readouts as described previously [4]. We observed that both Pegasys and nafamostat reduced SARS-CoV-2-mediated mCherry expression and rescued cells from virus-mediated death (Fig. 1a). Interestingly, Pegasys reduced SARS-CoV-2 replication less efficiently than its non-pegylated analogue, whereas nafamostat reduced SARS-CoV-2 replication more efficiently than camostat.

Second, we examined whether Pegasys-nafamostat can inhibit SARS-CoV-2 infection and protect Calu-3 cells from virus-mediated death more efficiently and at lower concentrations than monotherapies. We tested the antiviral efficacy and toxicity of the combination by monitoring SARS-CoV-2-mediated mCherry expression and cell viability. The drug combination was tested in a 6×6 dose-response matrix, where 5 doses of each combination component are combined in a pairwise manner. As a result, we obtained dose-response matrices demonstrating virus inhibition and cell viability (Fig. 1b). We plotted synergy distribution maps, showing synergy (higher than expected effect) at each pairwise dose. We calculated average ZIP synergy scores for the whole 6×6 dose-response matrices and for most synergistic 3×3 dose-regions, summarizing combination synergies into single metrics. We observed strong synergy of the Pegasys-nafamostat combination (ZIP synergy scores: 4.8 (mCherry) and 27.4 (CTG); most synergistic area scores: 13.6 (mCherry) and 36.4 (CTG)). This strong synergy indicates that, both components could be combined in vitro at decreased concentrations to achieve antiviral efficacy comparable to those of individual drugs at high concentrations.

Next, we examined whether Pegasys-nafamostat can affect the replication of SARS-CoV-2 *in vivo* (Fig. 2a). Four groups of 6 six-week-old female Syrian hamsters were injected IP with 40 µg/kg Pegasys, 10 mg/kg nafamostat, Pegasys-nafamostat combination or vehicle at day 0, 1 and 2 of infection. After 2 h of drug treatment at day 0, the animals received SARS-CoV-2 strain Slovakia/SK-BMC5/2020 intranasally (10^5 pfu TCID₅₀ per animal). A control group of 5 hamsters remained untreated and uninfected. After 3 days, the animals were anesthetized and euthanized, and lungs were collected. Total RNA was extracted and polyadenylated RNA was sequenced. We found that the drug combination efficiently attenuated synthesis of viral and host RNA (Fig. 2c). We validated our results by analyzing expression of viral ORF1ab using RT-qPCR. We found that the antiviral effect of the combination was additive (synergy score: 5.17; Fig. 2d), suggesting that this cocktail has high translatability.

Our recent transcriptomics analysis revealed that IFNα activates transcription of many genes including endothelial plasminogen activator inhibitor (*SERPINE1*) in Calu-3 cells and human lung organoids [4]. Serpin E1 inhibits urokinase-type and tissue-type plasminogen activators (uPA and tPA) as well as various membrane-

84 anchored serine proteases including transmembrane protease serine 2 (TMPRSS2) [11]. Interestingly, nafamostat
85 also inhibits TMPRSS2 [12]. Therefore, we hypothesized that the synergy of the Pegasys-nafamostat could be
86 achieved because both drugs target the same host factor, TMPRSS2 (Fig. 2d). To investigate this, we treated a
87 group of 6 hamsters with an inhibitor of Serpin E1, tiplaxtinin (3 mg/kg, PO), Pegasys (40 µg/kg, IP), and
88 nafamostat (10 mg/kg, IP) at day 0, 1 and 2 of infection. After 2 h of drug treatment at day 0, the animals received
89 SARS-CoV-2 intranasally. After 3 days, the animals were anesthetized and euthanized, and lungs were collected.
90 Total RNA was extracted and polyadenylated RNA was sequenced. Tiplaxtinin treatment restored viral and host
91 RNA synthesis to the level of nafamostat alone, and therefore wholly eliminated the effect of Pegasys (Fig. 2c).
92 This was confirmed by RT-qPCR. Our results indicate that Serpin E1 is an essential mediator of IFNα activity and
93 that TMPRSS2 can be targeted by several drugs to synergistically suppress viral infection.

94 It was shown that nafamostat inhibits hypercoagulopathy associated with severe COVID-19 [7]. By
95 contrast, IFNα-induced Serpin E1 is a risk factor for thrombosis [13]. Thus, it is highly likely that the
96 anticoagulative properties of nafamostat could compensate for the adverse effects of IFNα-induced Serpin E1
97 when administered in combination with each other. Moreover, combination therapy containing lower doses of
98 Pegasys and nafamostat may reduce the likelihood of developing other side effects entirely [14], and thus be
99 useful in treating COVID-19 patients. In addition, the Pegasys-nafamostat combination could be delivered
100 through different administration routes, leading to greater ease of treatment. We believe further development of
101 combination of these two prescription drugs can lead to practical therapeutic options against many viruses for
102 which replication depends on TMPRSS2, including influenza viruses and other coronaviruses [15]. Furthermore,
103 our demonstrated proof-of-concept here shows that research on potential synergistic antiviral combinations can
104 have significant global impact, by increasing protection of the general population against emerging and re-
105 emerging viral diseases and filling the time between virus identification and vaccine development with life-
106 saving countermeasures.

107 **Materials and methods**

108 *Drugs, viruses, cells, and hamsters*

109 Pegasys (cat. # EMEA/H/C/000395, 008767) was purchased from local pharmacy in syringes for
110 subcutaneous injection (135µg IFNα2a/0.5mL each). Lyophilized IFNα2a (cat. # 11343504;
111 ImmunoTools) was dissolved in sterile deionized water to obtain 200 µg/mL concentrations.

Camostat mesylate (cat. # 16018, Cayman Chemicals), nafamostat mesylate (cat. # 14837, Cayman Chemicals) and tiplaxtinin (cat. # 393105-53-8, MCE) were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) to obtain 10 mM stock solutions.

Recombinant mCherry-expressing SARS-CoV-2 (SARS-CoV-2-mCherry), and wild type human SARS-CoV-2 strains were provided by Prof. Andres Merits or the European Virus Archive global (EVAg) and propagated in Vero E6 or Vero E6/TMPRSS2 cells. To quantitate the production of infectious virions, we titrated the viruses using plaque assays or ELISA.

The propagation of human non-small cell lung cancer Calu-3 have been described in our previous studies [4, 16].

Thirty-five 6-week-old healthy female Syrian hamsters were obtained from Janvier Labs. The animals were maintained in pathogen free health status according to the FELASA guidelines. The animals were individually identified and were maintained in housing rooms under controlled environmental conditions: temperature: $21 \pm 2^{\circ}\text{C}$, humidity $55 \pm 10\%$, photoperiod (12h light/12h dark), H14 filtered air, minimum of 12 air exchanges per hour with no recirculation. Each cage was labeled with a specific code. Animal enclosures provided sterile and adequate space with bedding material, food and water, environmental and social enrichment (group housing) as described below: IsoRat900N biocontainment system (Techniplast, France), poplar bedding (Select fine, Safe, France), A04 SP-10 diet (Safe, France), tap water, environmental enrichment, tunnel, wood sticks.

Drug Testing and Drug Sensitivity Quantification

Approximately 4×10^4 Calu-3 cells were seeded per well in 96-well plates. The cells were grown for 24 h in DMEM-F12, supplemented with 10% FBS and Pen–Strep. The medium was then replaced with DMEM-F12 containing 0.2% BSA, Pen–Strep and the compounds in 5-fold dilutions at 7 different concentrations. No compounds were added to the control wells. The cells were infected with SARS-CoV-2-mCherry strains at a moi of 0.1 or mock. After 48h drug efficacy on SARS-CoV-2-mCherry

infected cells was measured on PFA- or acetone-fixed cells with fluorescence. After 72 h of infection, a CellTiter-Glo (CTG) assay was performed to measure cell viability.

The half-maximal cytotoxic concentration (CC_{50}) for each compound was calculated based on viability/death curves obtained on mock-infected cells after non-linear regression analysis with a variable slope using GraphPad Prism software version 7.0a. The half-maximal effective concentrations (EC_{50}) were calculated based on the analysis of the viability of infected cells by fitting drug dose-response curves using four-parameter (4PL) logistic function $f(x)$:

$$f(x) = A_{min} + \frac{A_{max} - A_{min}}{1 + \left(\frac{x}{m}\right)^{\lambda}}, \quad (1)$$

where $f(x)$ is a response value at dose x , A_{min} and A_{max} are the upper and lower asymptotes (minimal and maximal drug effects), m is the dose that produces the half-maximal effect (EC_{50} or CC_{50}), and λ is the steepness (slope) of the curve. The relative effectiveness of the drug was defined as selectivity index ($SI = CC_{50}/EC_{50}$).

Drug Combination Testing and Synergy Calculations

Calu-3 cells were treated with different concentrations of two drugs and infected with SARS-CoV-2-mCherry (moi 0.1) or mock. After 48 h, cell viability and reporter protein expression were measured. To test whether the drug combinations act synergistically, the observed responses were compared with expected combination responses. The expected responses were calculated based on the ZIP reference model using SynergyFinder version 2 [17, 18]. Final synergy scores were quantified as average excess response due to drug interactions (i.e., 10% of cell survival beyond the expected additivity between single drugs represents a synergy score of 10). Additionally, we calculated most synergistic area scores for each drug combination – the most synergistic 3-by-3 dose-window in dose-response matrixes.

Prophylactic Study of Remdesivir, IFN α and Their Combination Against SARS-CoV-2 Infection in Hamsters

Thirty-five animals were weighed and divided into 6 homogenous groups of 5-6 animals. Group 1 (5 non-infected controls) remained unmanipulated. Group 2 received vehicle (10mL/kg) 3 times by IP route on Day 0 (t-2h), Day 1 and Day 2. Group 3 received nafamostat (10mg/kg) 3 times by IP route on Day 0 (t-2h), Day 1 and Day 2. Group 4 received Pegasys (40 µg/kg) 3 times by IP route on Day 0 (t-2h), Day 1 and Day 2. Group 5 received a mixture of nafamostat and Pegasys 3 times by IP route on Day 0 (t-2h), Day 1 and Day 2. Group 6 received a mixture of the nafamostat and Pegasys 3 times by IP route on Day 0 (t-2h), Day 1 and Day 2 and Tiplaxtinin (3mg/kg) 3 times by PO route on Day 0 (t-2h), Day 1 and Day 2. Groups 2-6 received SARS-CoV-2 intranasally. Animal viability, behavior and clinical parameters were monitored daily. After 3 days animals were deeply anesthetized using a cocktail of 30 mg/kg (0.6 mL/kg) Zoletil and 10 mg/kg (0.5 mL/kg) Xylazine IP. Cervical dislocation followed by thoracotomy was performed before lung collection. The entire left lungs and superior, middle, post-caval and inferior lobes of right lungs were put in RNAlater tissue storage reagent overnight at 4°C, then stored at -80°C until RNA extraction.

Gene Expression Analysis

Total RNA was isolated using RNeasy Plus Mini kit (Qiagen, Hilden, Germany) from lungs of Syrian hamsters. Polyadenylated mRNA was isolated from 250 ng of total RNA with NEBNext Poly(A) mRNA magnetic isolation module. NEBNext Ultra II Directional RNA Library Prep kit from Illumina was used to prepare samples for sequencing. Sequencing was done on NextSeq 500 instrument (set up: single-end 1 x 76 bp + dual index 8 bp) using NextSeq High Output 75 cycle sequencing kit (up to 400M reads per flow cell). Reads were aligned using the Bowtie 2 software package version 2.4.2 to the NCBI reference sequence for SARS-CoV-2 (NC_045512.2) and to the *Mesocricetus auratus* MesAur1.0 assembly genome (https://ftp.ensembl.org/pub/release-100/fasta/mesocricetus_auratus/dna/). The number of mapped and unmapped reads that aligned to each gene were obtained with the featureCounts function from Rsubread R-package version 2.10. The GTF table for the SARS-CoV-2 reference sequence was downloaded from

https://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/009/858/895/GCF_009858895.2_SM985889v3/GCF_009858895.2_ASM985889v3_genomic.gtf.gz. The heatmaps were generated using the pheatmap package (<https://cran.r-project.org/web/packages/pheatmap/index.html>) based on log2-transformed or non-transformed profiling data.

RT-PCR was performed using SuperScript™ III One-Step qRT-PCR System kit (commercial kit #1732-020, Life Technologies) with primers ORF1ab_Fw: CCGCAAGGTTCTTCTTCGTAAG, ORF1ab_Rv: TGCTATGTTTAGTGTCCAGTTTTC, ORF1ab_probe: Hex-AAGGATCAGTGCCAAGCTCGTCGCC-BHQ-1 targeting a region on ORF1ab. RT-qPCR was performed using a Bio-Rad CFX384™ and adjoining software. The relative gene expression differences were calculated using β -Actin as control and the results were represented as relative units (RU). Technical triplicates of each sample were performed on the same qPCR plate and non-templates and non-reverse transcriptase samples were analysed as negative controls. Statistical significance ($p < 0.05$) of the quantitation results was evaluated with t-test. Benjamini-Hochberg method was used to adjust the p-values.

Ethics approval and consent to participate: Standard operational procedures were approved by institutional safety committee. Animal housing and experimental procedures were conducted according to the French and European Regulations and the National Research Council Guide for the Care and Use of Laboratory Animals. The animal BSL3 facility is authorized by the French authorities (Agreement N° D92-032-02). All animal procedures (including surgery, anesthesia, and euthanasia as applicable) were approved by the Institutional Animal Care and Use Committee of CEA and French authorities (CETEA DSV – n° 44).

Consent for publication: All authors have read and agreed to the published version of the manuscript.

Availability of data and material: All data generated or analyzed during this study are included in this published article and its supplementary information files.

Competing interests: Authors declare no competing interests.

Author Contributions: All authors contributed to the methodology, software, validation, formal analysis, investigation, resources, data curation, writing, and review and editing of the manuscript.

D.K. conceptualized, supervised, and administrated the study and acquired funding.

Funding: This research was funded by the European Regional Development Fund, the Mobilitas Pluss Project MOBTT39 (to D.K.).

Acknowledgments: We thank personnel of Oncodesign for animal experiment.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Consortium, W.H.O.S.T., et al., Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*, 2021. **384**(6): p. 497-511.
2. Ianevski, A., et al., Identification and Tracking of Antiviral Drug Combinations. *Viruses*, 2020. **12**(10).
3. Alavi Darazam, I., et al., Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. *Sci Rep*, 2021. **11**(1): p. 8059.
4. Ianevski, A., et al., Interferon alpha-based combinations suppress SARS-CoV-2 infection in vitro and in vivo. *bioRxiv*, 2021: p. 2021.01.05.425331.
5. Hung, I.F., et al., Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet*, 2020. **395**(10238): p. 1695-1704.
6. Doi, K., et al., Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. *Crit Care*, 2020. **24**(1): p. 392.
7. Sundaram, S., et al., Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. *Thromb Haemost*, 1996. **75**(1): p. 76-82.

- 235 8. Pandit, A., et al., Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A
236 phase II, randomized, controlled, open-label study. *Int J Infect Dis*, 2021. **105**: p. 516-521.
- 237 9. Yu, J., et al., Interferon-alpha-2b aerosol inhalation is associated with improved clinical
238 outcomes in patients with coronavirus disease-2019. *Br J Clin Pharmacol*, 2021.
- 239 10. Rihn, S.J., et al., A plasmid DNA-launched SARS-CoV-2 reverse genetics system and
240 coronavirus toolkit for COVID-19 research. *PLoS Biol*, 2021. **19**(2): p. e3001091.
- 241 11. Sillen, M. and P.J. Declerck, A Narrative Review on Plasminogen Activator Inhibitor-1 and Its
242 (Patho)Physiological Role: To Target or Not to Target? *Int J Mol Sci*, 2021. **22**(5).
- 243 12. Kaur, U., et al., Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. *Curr Drug*
244 *Targets*, 2021. **22**(2): p. 192-201.
- 245 13. Rau, J.C., et al., Serpins in thrombosis, hemostasis and fibrinolysis. *J Thromb Haemost*, 2007. **5**
246 **Suppl 1**: p. 102-15.
- 247 14. Vallbracht, A., et al., Interferon-neutralizing antibodies in a patient treated with human
248 fibroblast interferon. *Nature*, 1981. **289**(5797): p. 496-7.
- 249 15. Shen, L.W., et al., TMPRSS2: A potential target for treatment of influenza virus and
250 coronavirus infections. *Biochimie*, 2017. **142**: p. 1-10.
- 251 16. Ko, M., et al., Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from
252 South Korea Identifies Potential Therapeutic Options for COVID-19. *Viruses*, 2021. **13**(4).
- 253 17. Ianevski, A., et al., SynergyFinder: a web application for analyzing drug combination dose-
254 response matrix data. *Bioinformatics*, 2017. **33**(15): p. 2413-2415.
- 255 18. Ianevski, A., A.K. Giri, and T. Aittokallio, SynergyFinder 2.0: visual analytics of multi-drug
256 combination synergies. *Nucleic Acids Res*, 2020. **48**(W1): p. W488-W493.

257

Figure 1. Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection *in vitro*.

(a) Pegasys and nafamostat attenuate virus-mediated reporter protein expression and rescue Calu-3 cells from SARS-CoV-2-mediated death. Calu-3 cells were treated with increasing concentrations of Pegasys or nafamostat and infected with the SARS-CoV-2-mCherry or mock. After 48 h, the virus-mediated mCherry expression was measured (red curves). After 72 h, viability of virus- and mock-infected cells was determined using a CTG assay (yellow and blue curves, respectively). Mean $\pm$ SD; n = 3. Toxicity and anti-SARS-CoV-2 activity of Pegasys and nafamostat was quantified and compared to that of IFNa2a and camostat.

(b) Pegasys and nafamostat combination act synergistically against SARS-CoV-2-mCherry infection in Calu-3 cells. Calu-3 cells were treated with increasing concentrations of IFNa2a, nafamostat or both drugs and infected with the SARS-CoV-2-mCherry or mock. After 48 h, the virus-mediated mCherry expression was measured (red curves). After 72 h, viability of virus- and mock-infected cells was determined using a CTG assay (yellow and blue curves, respectively). The 6 $\times$ 6 dose-response matrices and interaction landscapes of the drug combination was obtained using fluorescence analysis as well as cell viability assay (CTG) on mock-, and SARS-CoV-2-mCherry-infected Calu-3 cells. ZIP synergy score was calculated for the drug combinations. The selectivity for the indicated drug concentrations was calculated (selectivity = efficacy-(100-Toxicity)). ZIP synergy scores were calculated for indicated drug combinations. Representative matrices and interaction landscapes are shown (n = 2).

Figure 2. Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection *in vivo*.

(a) Schematic representation of the experimental setup.

(b, c) Heatmaps of host and viral polyadenylated RNAs affected by treatment. Each cell is colored according to the log₂-transformed expression values of the samples, expressed as fold-change relative to the nontreated mock-infected control. Mean, n = 6 (except control group, where n = 5).

(d) RT-qPCR analysis of selected viral RNA (right panel). Expression of viral RNA was normalized to b-actin control. Mean $\pm$ SD, n = 6 (except control group, where n = 5). Statistically significant differences in viral gene expression between non-treated and treated animals are indicated with asterisks (one-way ANOVA with post-hoc Tukey HSD test, ** - p < 0.3).

(e) Schematic representation of synergistic mechanism of action of Pegasys and nafamostat: Pegasys-nafamostat combination acted synergistically against wild-type SARS-CoV-2 strain in Syrian hamsters, whereas tiplaxtinin wholly eliminated the effect of Pegasys.